<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851877</url>
  </required_header>
  <id_info>
    <org_study_id>STU 072010-046</org_study_id>
    <secondary_id>SCCC-112008-019</secondary_id>
    <secondary_id>CDR0000634258</secondary_id>
    <nct_id>NCT00851877</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
      formulation and cisplatin, work in different ways to stop the growth of tumor cells, either
      by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
      cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to
      grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances
      to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Paclitaxel
      albumin-stabilized nanoparticle formulation may make tumor cells more sensitive to radiation
      therapy. Giving radiation therapy and paclitaxel albumin-stabilized nanoparticle formulation
      together with cisplatin and cetuximab may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel
      albumin-stabilized nanoparticle formulation when given together with cisplatin, cetuximab,
      and radiation therapy to see how well they work in treating patients with locally advanced
      stage III or stage IV head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the maximum tolerated dose of paclitaxel albumin-stabilized nanoparticle
           formulation when combined with cisplatin, cetuximab, and radiotherapy in patients with
           local-regionally advanced squamous cell carcinoma of the head and neck. (Phase I)

        -  To evaluate the disease-free survival of patients treated with this regimen. (Phase II)

      Secondary

        -  To identify dose-limiting toxicities in these patients treated with this regimen. (Phase
           I)

        -  To assess the safety and tolerability of this regimen. (Phases I and II)

        -  To assess progression-free survival and survival of patients treated with this regimen.
           (Phase I)

        -  To assess overall survival in patients treated with this regimen. (Phase II)

        -  To assess response rates in patients treated with this regimen. (Phases I and II)

      OUTLINE: This is a multicenter, phase I dose-escalation study of paclitaxel
      albumin-stabilized nanoparticle formulation followed by a phase II study.

      Patients receive cetuximab IV over 120 minutes in week 1. Patients then receive cetuximab IV
      over 60 minutes, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes,
      and cisplatin IV over 60 minutes once weekly in weeks 2-8. Patients also undergo 3D conformal
      or intensity-modulated radiotherapy over 30 minutes on days 1-5 in weeks 2-8.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2009</start_date>
  <completion_date type="Actual">August 3, 2015</completion_date>
  <primary_completion_date type="Actual">October 1, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Maximum Tolerated Dose of Nab-Paclitaxel</measure>
    <time_frame>90 days</time_frame>
    <description>Seven participants were assigned nab-paclitaxel in dose of 25mg/m^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II 2-year Progression-free Survival</measure>
    <time_frame>2 year</time_frame>
    <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
The primary endpoint of 2-year progression-free survival was measured from the date of enrollment to the first occurrence of new metastatic lesion, objective tumor progression, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II 2-year Local Control</measure>
    <time_frame>2 year</time_frame>
    <description>Local control is defined as the arrest cancer growth at the site of origin. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II 2-year Overall Survival</measure>
    <time_frame>2 year</time_frame>
    <description>median follow-up 24 months for 34 patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>arm one</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor</description>
    <arm_group_label>arm one</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is an anti-cancer chemotherapy drug</description>
    <arm_group_label>arm one</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>paclitaxel albumin-stabilized nanoparticle formulation</description>
    <arm_group_label>arm one</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>intensity-modulated radiation therapy</description>
    <arm_group_label>arm one</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the oropharynx, hypopharynx, or
             larynx

               -  Diagnosis based on the primary lesion and/or lymph nodes

               -  Stage III or IV disease (T2, N2-3, M0 or T3-4, any N, M0)

          -  No primary tumor of the oral cavity, nasopharynx, sinuses, or salivary glands

          -  No distant metastasis by chest x-ray, CT scan, or PET/CT scan within the past 6 weeks

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  ANC &gt; 1,500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 9.0 g/dL (transfusion or other intervention to achieve hemoglobin &gt; 8.0
             g/dL allowed)

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST, ALT, and AP ≤ 2.5 times upper limit of normal

          -  Serum creatinine ≤ 1.5 mg/dL

          -  Creatinine clearance ≥ 50 mL/min

          -  None of the following electrolyte abnormalities grade 3-4 by CTCAE v 3.0:

               -  Calcium &lt; 7 mg/dL or &gt; 12.5 mg/dL

               -  Glucose &lt; 40 mg/dL or &gt; 250 mg/dL

               -  Magnesium &lt; 0.9 mg/dL or &gt; 3 mg/dL

               -  Potassium &lt; 3 mmol/L or &gt; 6 mmol/L

               -  Sodium &lt; 130 mmol/L or &gt; 155 mmol/L

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other prior invasive malignancy, except for nonmelanomatous skin cancer, unless
             disease-free for ≥ 3 years

          -  No prior allergic reaction to study drugs

          -  No active cardiac disease, defined as any of the following:

               -  Unstable angina

               -  Uncontrolled hypertension

               -  Myocardial infarction within the past 6 months (unless successfully treated with
                  coronary artery bypass graft or percutaneous transluminal coronary angioplasty)

               -  Uncontrolled arrhythmia

               -  Congestive heart failure

               -  Three or more heart-related hospitalizations within the past year

          -  No severe chronic obstructive pulmonary disease requiring ≥ 3 hospitalizations within
             the past year

          -  No AIDS

          -  No pre-existing peripheral sensory neuropathy ≥ grade 2

          -  No concurrent medical illnesses that would impair patient tolerance to therapy or
             limit survival

        PRIOR CONCURRENT THERAPY:

          -  No prior systemic chemotherapy for this cancer

               -  Prior systemic chemotherapy for a different cancer allowed

          -  No prior radiotherapy to the region of this cancer that would result in overlap of
             radiotherapy fields

          -  No prior initial surgical treatment (excluding diagnostic biopsy of the primary site
             or nodal sampling of neck disease)

          -  At least 48 hours since prior and no concurrent granulocytic growth factors (e.g.,
             filgrastim [G-CSF]) during radiotherapy

          -  No concurrent erythropoietic growth factors (e.g., darbepoetin, erythropoietin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hak Choy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <results_first_submitted>January 12, 2018</results_first_submitted>
  <results_first_submitted_qc>July 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I Nab-paclitaxel 25 mg/m^2</title>
          <description>Cetuximab 450mg/m^2 as a loading dose in week one. Cetuximab 250 mg/m^2, Cisplatin 20mg/m^2 and nab-paclitaxel 25mg/m^2 weekly, concurrent with 70 Gy in 35 fractions continuous course intensity modulated radiotherapy during weeks 2-8.</description>
        </group>
        <group group_id="P2">
          <title>Phase I Nab-paclitaxel 20mg/m^2</title>
          <description>Cetuximab 450mg/m^2 as a loading dose in week one. Cetuximab 250 mg/m^2, Cisplatin 20mg/m^2 and nab-paclitaxel 20mg/m^2 weekly, concurrent with 70 Gy in 35 fractions continuous course intensity modulated radiotherapy during weeks 2-8.</description>
        </group>
        <group group_id="P3">
          <title>Phase II Nab-paclitaxel 20mg/m^2</title>
          <description>Cetuximab 450mg/m^2 as a loading dose in week one. Cetuximab 250 mg/m^2, Cisplatin 20mg/m^2 and nab-paclitaxel 20mg/m^2 weekly, concurrent with 70 Gy in 35 fractions continuous course intensity modulated radiotherapy during weeks 2-8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I-1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I-2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nab-Paclitaxel, Cisplatin, Cetuximab and Radiation Therapy</title>
          <description>Phase I/II Cetuximab, Cisplatin and nab-paclitaxel concurrent with intensity-modulated radiotherapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="45" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I Maximum Tolerated Dose of Nab-Paclitaxel</title>
        <description>Seven participants were assigned nab-paclitaxel in dose of 25mg/m^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m^2.</description>
        <time_frame>90 days</time_frame>
        <population>12 patients enrolled in the phase I study.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy</title>
            <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Cisplatin: Cisplatin is an anti-cancer chemotherapy drug
Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation
intensity-modulated radiation therapy: intensity-modulated radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Maximum Tolerated Dose of Nab-Paclitaxel</title>
          <description>Seven participants were assigned nab-paclitaxel in dose of 25mg/m^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m^2.</description>
          <population>12 patients enrolled in the phase I study.</population>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II 2-year Progression-free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
The primary endpoint of 2-year progression-free survival was measured from the date of enrollment to the first occurrence of new metastatic lesion, objective tumor progression, or death.</description>
        <time_frame>2 year</time_frame>
        <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy</title>
            <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Cisplatin: Cisplatin is an anti-cancer chemotherapy drug
Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation
intensity-modulated radiation therapy: intensity-modulated radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II 2-year Progression-free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
The primary endpoint of 2-year progression-free survival was measured from the date of enrollment to the first occurrence of new metastatic lesion, objective tumor progression, or death.</description>
          <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="42" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II 2-year Local Control</title>
        <description>Local control is defined as the arrest cancer growth at the site of origin. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions</description>
        <time_frame>2 year</time_frame>
        <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy</title>
            <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Cisplatin: Cisplatin is an anti-cancer chemotherapy drug
Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation
intensity-modulated radiation therapy: intensity-modulated radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II 2-year Local Control</title>
          <description>Local control is defined as the arrest cancer growth at the site of origin. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions</description>
          <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="55" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II 2-year Overall Survival</title>
        <description>median follow-up 24 months for 34 patients</description>
        <time_frame>2 year</time_frame>
        <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Nab-Paclitaxel, Cisplatin, Cetuximab and Radiation Therapy</title>
            <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Cisplatin: Cisplatin is an anti-cancer chemotherapy drug
Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation
intensity-modulated radiation therapy: intensity-modulated radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II 2-year Overall Survival</title>
          <description>median follow-up 24 months for 34 patients</description>
          <population>12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="50" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, and average of 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nab-Paclitaxel, Cisplatin, Cetuximab and Radiation Therapy</title>
          <description>Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
Cisplatin: Cisplatin is an anti-cancer chemotherapy drug
Nab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation
intensity-modulated radiation therapy: intensity-modulated radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Nab-Paclitaxel toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>grade 4 larynx edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypothyroidism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>larynx edema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>xerostomia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fibrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trial</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <email>ClinicalTrials@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

